Clinical significance and application of midregional pro-atrial natriuretic peptide
10.3760/cma.j.issn.1009-9158.2014.07.006
- VernacularTitle:中间片段心房利钠肽原研究现状及应用前景
- Author:
Xiuming ZHANG
- Publication Type:Journal Article
- Keywords:
Heart failure;
Atrial natriuretic factor;
Biological markers;
Prognosis
- From:
Chinese Journal of Laboratory Medicine
2014;37(7):501-504
- CountryChina
- Language:Chinese
-
Abstract:
B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) have been widely used in the diagnosis and management of heart failure (HF).In recent years,some new biomarkers emerged in different pathophysiological procedure of HF development,such as myocardial injury,myocarditis,myocardial remodeling,etc.Mid-regional proatrial natriuretic peptide (MR-proANP),one of the most deeply researched and widely used emerging biomarkers,has been reported that it has the same value in HF diagnosis and is better in HF prognosis,compared with BNP and NT-proBNP.MR-proANP could also be an independent factor in HF diagnosis and prognosis.However,further research is still needed in risk assessment of cardiovascular event.
